- increased circulating LDL cholesterol level / IMPC
- decreased hematocrit / IMPC
- abnormal eye morphology / IMPC
- increased mean platelet volume / IMPC
- decreased hemoglobin content / IMPC
- decreased erythrocyte cell number / IMPC
- increased circulating alkaline phosphatase level / IMPC
- thrombocytopenia / IMPC
- increased lean body mass / IMPC
- increased circulating cholesterol level / IMPC
- improved glucose tolerance / IMPC
- increased circulating aspartate transaminase level / IMPC
- decreased circulating serum albumin level / IMPC
- decreased circulating glucose level / IMPC
- increased red blood cell distribution width / IMPC
- decreased circulating fructosamine level / IMPC
- decreased fasting circulating glucose level / IMPC
C57BL/6N-Irgm1em1(IMPC)Wtsi/WtsiCnbc
Status | Available to order |
EMMA ID | EM:14780 |
Citation information | RRID:IMSR_EM:14780 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information. |
International strain name | C57BL/6N-Irgm1em1(IMPC)Wtsi/WtsiCnbc |
Alternative name | |
Strain type | Endonuclease-mediated |
Allele/Transgene symbol | Irgm1em1(IMPC)Wtsi |
Gene/Transgene symbol | Irgm1 |
Information from provider
Provider | Wellcome Trust Sanger Institute |
Provider affiliation | Wellcome Trust Sanger Institute |
Genetic information | This mouse line originates from CRISPR zygote microinjection. For further details see the project page at the IMPC portal. |
Phenotypic information | Potential phenotyping data in the IMPC portal |
References | None available |
Information from EMMA
Archiving centre | CNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain |
Animals used for archiving | heterozygous C57BL/6N males |
Disease and phenotype information
IMPC phenotypes (allele matching)
IMPC phenotypes (gene matching)
- increased circulating aspartate transaminase level / IMPC
- increased lean body mass / IMPC
- decreased circulating glucose level / IMPC
- increased circulating alkaline phosphatase level / IMPC
- decreased erythrocyte cell number / IMPC
- increased red blood cell distribution width / IMPC
- improved glucose tolerance / IMPC
- decreased circulating fructosamine level / IMPC
- decreased hemoglobin content / IMPC
- thrombocytopenia / IMPC
- abnormal eye morphology / IMPC
- decreased fasting circulating glucose level / IMPC
- decreased circulating serum albumin level / IMPC
- increased mean platelet volume / IMPC
- increased circulating LDL cholesterol level / IMPC
- decreased hematocrit / IMPC
- increased circulating cholesterol level / IMPC
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).